[Study of propoleum dosage in Peyronie's disease].
OBJECTIVE
To determine the optimal dose for propoleum caps in Peyronie's disease.


METHODS
We evaluated two groups of 17 patients each, analyzing pain and plaque size on physical and ultrasound examination, before and after treatment. Group A patients received caps with 300 mg of propoleum powder daily for six months, and Group B 900 mg.


RESULTS
Predominant ages were between 41 and 70 years. More than half the patients in group A had pain; more than half the patients in group B did not have pain; considering both groups there were more patients without pain. Physical reduction of the plaque: Group A: 0.6 cm, Group B: 0.8 cm. Ultrasound reduction of the plaque: Group A: 1.3 cm, Group B: 0.8 cm. In the higher dose group (B) clinical and ultrasound improvement started earlier. 79.4% of the treated patients evaluated preferred improvement or slight improvement, being this result statistically significant.


CONCLUSIONS
Pain is not always an accompanying symptom in Peyronie's disease. Both doses administered reduced the size of the plaque, but the higher one has an earlier improvement. We may consider propoleum administered in this way another treatment option for this disease, with good results and low cost.
Servicio de Urología, Hospital Docente Quirúrgico Freyre de Andrade, La Habana, Cuba. malem@infomed.sld.cu
Manuel
M
Lemourt Oliva
Ada
A
Rodríguez Barroso
Rafaela
R
Bordonado Ramírez
Elizabeth
E
González Oramas
Félix
F
Molina Castillo
D000276:Adjuvants, Immunologic / Q000627:therapeutic use*; D000328:Adult; D000368:Aged; D001688:Biological Products / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D010411:Penile Induration / Q000188:drug therapy*
D000276:Adjuvants, Immunologic; D001688:Biological Products